Mein Warenkorb

LIGHT

LIGHT Molekülinformation

Englischer NameTumor necrosis factor superfamily member 14Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel1Target-AliasCD258 Antigen,Herpes Virus Entry Mediator Ligand,TNFSF14,Herpesvirus Entry Mediator Ligand,LIGHT,Tumor Necrosis Factor (Ligand) Superfamily, Member 14,CD258,HVEM-L,Tumor Necrosis Factor Ligand 1D,LTg,HVEML,TNF Superfamily Member 14,Tumor Necrosis Factor Ligand Superfamily Member 14,Tumor Necrosis Factor Superfamily Member 14
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameTumor necrosis factor superfamily member 14
Target-AliasCD258 Antigen,Herpes Virus Entry Mediator Ligand,TNFSF14,Herpesvirus Entry Mediator Ligand,LIGHT,Tumor Necrosis Factor (Ligand) Superfamily, Member 14,CD258,HVEM-L,Tumor Necrosis Factor Ligand 1D,LTg,HVEML,TNF Superfamily Member 14,Tumor Necrosis Factor Ligand Superfamily Member 14,Tumor Necrosis Factor Superfamily Member 14
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel1
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

LIGHT Molekülhintergrund

Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.

LIGHT Molekülalias

CD258 antigen,CD258,HVEM-L,LIGHT,LTg,TNFSF14,TR2,HVEML

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
QuisovalimabCERC-002; AEVI-002; MDGN-002; SAR-252067; AVTX-002Phase 2 ClinicalKyowa Hakko Kirin Co Ltd, La Jolla Pharmaceutical CompanyAcute Lung Injury; Asthma; Colitis, Ulcerative; Coronavirus Disease 2019 (COVID-19); Crohn Disease; Respiratory Distress Syndrome, Adult
Details

Produktrezensionen

  • E***a2021-09-23
    1Menschen mögen
    We use this protein as an ELISA standard. We are interested in quantifying soluble LIGHT concentration from human serum. This active form of the protein perfectly binds its receptors and policlonal antibodies. The standard curve obtained is highly reproducible. It was very easy to find all the information in the web of AcroBiosystems and to download the CoA, which was also very descriptive.
  • Molekülinformation
  • Produktliste
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns